Indatraline
Indatraline is a non-selective monoamine transporter inhibitor that was researched as a potential treatment for cocaine addiction and depression. It was developed in the 1990s by the pharmaceutical company Eli Lilly and Company.
Pharmacology[edit | edit source]
Indatraline inhibits the reuptake of serotonin, norepinephrine, and dopamine by binding to the transporters, and this leads to increased extracellular concentrations of these neurotransmitters and therefore an increase in neurotransmission.
Development and Research[edit | edit source]
Indatraline was developed by Eli Lilly and Company in the 1990s. It was researched as a potential treatment for depression and cocaine addiction. In animal studies, indatraline was shown to reduce cocaine use. However, development was discontinued due to the risk of seizures.
Side Effects[edit | edit source]
The most serious side effect of indatraline is the risk of seizures, which led to the discontinuation of its development. Other side effects include insomnia, nausea, and headache.
See Also[edit | edit source]
Indatraline Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD